← Human Trials & Peer-Reviewed Studies
Disparate systemic and renal blocking properties of angiotensin II antagonists during exogenous angiotensin II administration: implications for treatment
Plain-language guide to PMID 15361886 (2004): double-blind randomized controlled trial of Angiotensin II in 13 patients.
Key Facts
- PMID
- 15361886
- Journal
- Journal of human hypertension
- Year
- 2004
- Study type
- Randomized Controlled Trial
- Authors
- Willemsen JM et al. (4 authors)
- DOI
- 10.1038/sj.jhh.1001769
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Angiotensin II, published as a randomized controlled trial.
Generation of angiotensin II (Ang II) contributes to the pathogenesis of cardiovascular diseases.
Owing to the existence of high levels of Ang II within the kidney, blockade of the intrarenal Ang II levels may be important since long term outcome seems not only to be related to blood pressure per se.
Who Took Part
The study group was 13 patients.
By PubMed's age tags, the people studied were children, adults, middle-aged adults and older adults, women only.
How the Study Was Run
The design is described as randomized, double-blind, placebo-controlled and crossover.
Because people in this Angiotensin II study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
As a double-blind Angiotensin II study, the assignments were hidden from both participants and investigators until the end.
Some patients received a placebo instead of Angiotensin II, giving a reference point.
In the crossover set-up each of the patients took both Angiotensin II and the comparison in turn, acting as their own control.
What Was Measured
Owing to the existence of high levels of Ang II within the kidney, blockade of the intrarenal Ang II levels may be important since long term outcome seems not only to be related to blood pressure per se.
PubMed files the paper under topics including Angiotensin II, Angiotensin II Type 1 Receptor Blockers, Benzimidazoles, Biphenyl Compounds, Hemodynamics, Hypertension and Kidney.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Angiotensin II in 13 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2004 (Journal of human hypertension), a journal based in England.
More context: the Angiotensin II compound page, all human trials.
Our Notes on the Compound
Angiotensin II: An 8-amino-acid hormone that narrows blood vessels; synthetic angiotensin II (Giapreza) is used for low blood pressure in shock.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.